Most Read Articles
2 days ago
Tetanus toxoid 5 Lf, diphtheria toxoid 2 Lf, pertussis toxoid 2.5 mcg, filamentous haemagglutinin 5 mcg, fimbriae types 2 and 3 5 mcg, pertactin 3 mcg
Pearl Toh, 22 Oct 2020
The combination therapy comprising carfilzomib, cyclophosphamide and dexamethasone (KCd) is effective, with a tolerable safety profile, in an Asian cohort with high-risk multiple myeloma (MM) — thus providing a more economical alternative as a potential upfront regimen in resource-limited settings, according to leading experts during a myeloma education webinar.
Jairia Dela Cruz, Yesterday
The selective serotonin reuptake inhibitor escitalopram holds promise in the prevention of Alzheimer’s disease, reducing amyloid-β-42 levels in cerebrospinal fluid and brain tissue in older adults with normal cognitive function, according to recent evidence.
Roshini Claire Anthony, 13 Nov 2020

Diabetes is a key risk factor for heart failure (HF), which is the leading cause of hospitalization in patients with or without diabetes. SGLT-2* inhibitors (SGLT-2is) have been shown to reduce the risk of hospitalization for HF (HHF) regardless of the presence or absence of diabetes.

What are the predictors of melanoma after allogeneic HCT?

31 Aug 2020

Adherence to current surveillance guidelines, such as routine skin examination and photoprotection recommendations, is essential among survivors of haematopoietic cell transplantation (HCT) at highest risk for the development of cutaneous melanoma, suggests a recent study.

The investigators determined the risk factors for melanoma following allogeneic HCT by performing a nested case-control study of 140 melanoma patients and 557 controls (matched by age at HCT, sex, primary disease, and survival time) through the Center for International Blood and Marrow Transplant Research.

The risk of melanoma was significantly elevated among HCT survivors who received total body irradiation-based myeloablative conditioning (multivariable-adjusted odds ratio [OR], 1.77, 95 percent confidence interval [CI], 1.00–3.15) or reduced-intensity conditioning containing melphalan (OR, 2.60, 95 percent CI, 1.13–6.02) or fludarabine (OR, 2.72, 95 percent CI, 1.02–7.30) compared with busulfan-based myeloablative regimens.

Melanoma risk was also increased among HCT survivors who were diagnosed with acute graft-versus-host disease (GVHD) with stage 2+ skin involvement (OR, 1.92, 95 percent CI, 1.19–3.10), chronic GVHD without skin involvement (OR, 1.91, 95 percent CI, 1.03–3.57), or keratinocytic carcinoma (OR, 2.37, 95 percent CI, 1.16–4.83), as well as those residing in areas with higher ambient ultraviolet radiation (tertile 3 OR, 1.64, 95 percent CI, 1.01–2.67).

This study was limited by the lack of data on individual-level ultraviolet radiation exposure and clinical data on melanoma characteristics, according to the investigators, adding that misclassification of melanoma was possible since not all pathology reports were available for review.

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Doctor - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
2 days ago
Tetanus toxoid 5 Lf, diphtheria toxoid 2 Lf, pertussis toxoid 2.5 mcg, filamentous haemagglutinin 5 mcg, fimbriae types 2 and 3 5 mcg, pertactin 3 mcg
Pearl Toh, 22 Oct 2020
The combination therapy comprising carfilzomib, cyclophosphamide and dexamethasone (KCd) is effective, with a tolerable safety profile, in an Asian cohort with high-risk multiple myeloma (MM) — thus providing a more economical alternative as a potential upfront regimen in resource-limited settings, according to leading experts during a myeloma education webinar.
Jairia Dela Cruz, Yesterday
The selective serotonin reuptake inhibitor escitalopram holds promise in the prevention of Alzheimer’s disease, reducing amyloid-β-42 levels in cerebrospinal fluid and brain tissue in older adults with normal cognitive function, according to recent evidence.
Roshini Claire Anthony, 13 Nov 2020

Diabetes is a key risk factor for heart failure (HF), which is the leading cause of hospitalization in patients with or without diabetes. SGLT-2* inhibitors (SGLT-2is) have been shown to reduce the risk of hospitalization for HF (HHF) regardless of the presence or absence of diabetes.